scholarly journals Adaptive Platform Trials to Transform ALS Therapy Development

2021 ◽  
Author(s):  
Sabrina Paganoni ◽  
James D. Berry ◽  
Melanie Quintana ◽  
Eric Macklin ◽  
Benjamin R. Saville ◽  
...  
Keyword(s):  
2016 ◽  
Vol 5 (2) ◽  
pp. 101-107 ◽  
Author(s):  
Brian Huang ◽  
Nicholas A. E. Abbott ◽  
Linai Dacon ◽  
Siobhan McCormack ◽  
Ping Zhou ◽  
...  

2011 ◽  
Vol 37 (07) ◽  
pp. 834-839 ◽  
Author(s):  
Aisha Bruce ◽  
Mary Bauman ◽  
M. Patricia Massicotte

Chemistry ◽  
2021 ◽  
Vol 3 (3) ◽  
pp. 800-817
Author(s):  
Flavia Cavicchioli ◽  
Izzy M. Cesarotti ◽  
Madison Fangman ◽  
Josh Lua ◽  
Raymond Hautamaki ◽  
...  

Carbon monoxide (CO) has long been known for its toxicity. However, in recent decades, new applications for CO as a therapeutic compound have been proposed, and multiple forms of CO therapy have since been developed and studied. Previous research has found that CO has a role as a gasotransmitter and promotes anti-inflammatory and antioxidant effects, making it an avenue of interest for medicine. Such effects are possible because of the Nrf2/HO1 pathway, which has become a target for therapy development because its activation also leads to CO release. Currently, different forms of treatment involving CO include inhaled CO (iCO), carbon monoxide-releasing molecules (CORMs), and hybrid carbon monoxide-releasing molecules (HYCOs). In this article, we review the progression of CO studies to develop possible therapies, the possible mechanisms involved in the effects of CO, and the current forms of therapy using CO.


Rheumatology ◽  
2007 ◽  
Vol 46 (11) ◽  
pp. 1676-1683 ◽  
Author(s):  
A. English ◽  
E. A. Jones ◽  
D. Corscadden ◽  
K. Henshaw ◽  
T. Chapman ◽  
...  

2014 ◽  
Vol 13 (9) ◽  
pp. 949-960 ◽  
Author(s):  
Michele Simonato ◽  
Amy R Brooks-Kayal ◽  
Jerome Engel ◽  
Aristea S Galanopoulou ◽  
Frances E Jensen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document